|  | 
|  | 
| Active Org.- | 
|  | 
| Active Indication- | 
|  | 
| Drug Highest PhaseDiscontinued | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
100 Clinical Results associated with Theragene Pharmaceuticals, Inc.
0  Patents (Medical) associated with Theragene Pharmaceuticals, Inc.
20 May 2014·Journal of Clinical Oncology
Characterization of the mTOR autophosphorylation site, S2481, as a novel biomarker in renal cell carcinoma (RCC).
Author: Brooks, James D.  ; Harshman, Lauren Christine  ; Berglin, Jon  ; Hunter, Tony  ; Muller, Karra  ; Copp, Jeremy  ; Lin, Chii-Dean  ; Higgins, John 
4571 Background: mTOR inhibitors have clinical utility in VEGF-refractory RCC and may be useful in non-clear cell disease. In general, mTOR inhibition is inferior to targeting VEGF in the treatment...
100 Deals associated with Theragene Pharmaceuticals, Inc.
100 Translational Medicine associated with Theragene Pharmaceuticals, Inc.